CMPS COMPASS Pathways Plc

Biotech Analyst Ratings

Latest News

1. 12 May 2022 COMPASS Pathways to participate in upcoming Citi's Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference

   LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

   • Citi's Biopharma Virtual Co-Panel Day: panel "Mood Disorders/Mental Health Panel" at 11:00 am ET on 18 May 2022
   • HC Wainwright Global Investments Conference: presentation at 9:00 am ET on 24 May 2022

   A live audio webcast of both events will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following each event. For more information, please visit ir.compasspathways.com.
   

   About COMPASS…

   View Full Article
2. 10 May 2022 COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

   View Full Article
3. 09 May 2022 COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

   London, UK – 9 May 2022

   COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults.

   The double-blind, randomised, placebo-controlled study ("PSILAUT") will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin…

   View Full Article
4. 03 May 2022 Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund

   Catalio's Flagship Strategy Will Continue to Identify and Invest in Breakthrough Biomedical Technology Companies Founded by Serial Scientist-Entrepreneurs

   Catalio Capital Management, LP ("Catalio"), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III ("Fund III" or the "Fund"), with more than $381 million in total capital commitments, exceeding its original $300 million target. The Fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments.

   Launched in 2020 and led by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio manages more than $1 billion in…

   View Full Article
5. 03 May 2022 COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022

   LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2022, and provide an update on recent business developments on 10 May 2022.
   

   The management team will host a conference call at 8:00am ET (1:00pm UK) on 10 May. The call can be accessed by dialing (800) 926-7358 from the United States, +1 (212) 231-2914 internationally, and 0800 496 0823 from the UK, followed by the conference ID: 22018578.

   The call will also be webcast on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days.

   About…

   View Full Article